Daesung Microbiological Labs KRX:036480KOSDAQ
대성미생물 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days0
DART filings, 7 days0
Articles tracked0since Sep 11
In Q2 2026, Daesung Microbiological Labs reported revenue of ₩6.0bn, down 10.1% year on year, and an operating loss of ₩472m. Daesung Microbiological Labs (대성미생물) appeared in 0 Korean news articles and 0 DART filings over the past seven days.
Filing signals Swung to loss Screener
Daesung Microbiological Labs quarterly results separate, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩6.0bn | -10.1% | −₩472m margin −7.9% | – |
| Q1 2026 | ₩5.1bn | -2.3% | −₩516m margin −10.1% | – |
| Q4 2025 derived | ₩6.9bn | +1.9% | −₩270m margin −3.9% | ₩243m |
| Q3 2025 | ₩7.2bn | +23.5% | ₩591m margin 8.2% | ₩753m |
| Q2 2025 | ₩6.7bn | +19.3% | ₩728m margin 10.9% | −₩134m |
| Q1 2025 | ₩5.2bn | -7.0% | −₩334m margin −6.4% | −₩264m |
| Q4 2024 derived | ₩6.8bn | -5.0% | ₩729m margin 10.7% | – |
| Q3 2024 | ₩5.8bn | +2.7% | −₩941m margin −16.2% | – |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
Daesung Microbiological Labs top stories 2 weeks, by number of outlets
No story covered by multiple outlets in the past two weeks.
Latest Daesung Microbiological Labs news Korean headlines
No articles yet.